Cerenome Adds Blue Cross Blue Shield of Michigan, Expanding CNSide Coverage to 158M Lives
CNSY is trading near its 52-week low of $1.9 (5.3% above the low).
Summary
Cerenome's CNSide Diagnostics signed an in-network agreement with Blue Cross Blue Shield of Michigan, effective September 1, 2026, adding approximately 5 million covered lives and bringing total contracted coverage to about 158 million. This follows the HCSC agreement announced in August and the $20M financing facility with 3i, LP in September, showing continued execution of the national reimbursement strategy. The agreement is a material commercial milestone for a company with a $14.4M market cap and going concern doubt, as payer coverage directly drives physician adoption and test utilization. The company reported only $0.4M in Q2 revenue, so each new payer contract is critical to building the revenue base. Watch for additional payer agreements and Q3 revenue to see if coverage translates into test volume.
At the time of this announcement, CNSY was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $1.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.